caa a22 4500 386389438 CHVBK 20180307112109.0 cr unu---uuuuu 161130s1989 xx s 000 0 eng 10.1017/S026972700001071X doi S026972700001071X pii (NATIONALLICENCE)cambridge-10.1017/S026972700001071X Jordan V. Craig Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison, WI 53792, U.S.A. Optimisation of antioestrogen therapy: laboratory and clinical concepts [Elektronische Daten] [V. Craig Jordan] Tamoxifen, a non-steroidal antioestrogen, is the first line endocrine therapy for breast cancer. Laboratory studies during the past decade have provided valuable clues to understand the mode of action of tamoxifen so that the drug can be used to its best advantage in the clinic. Animal models (carcinogen-induced rat mammary carcinoma models, spontaneous mouse mammary tumours, and athymic mice inoculated with hormone-dependent human breast cancer cell lines) all demonstrate that tamoxifen is a tumouristatic agent and long-term or indefinite therapy is required to prevent the appearance of tumours. However, when treatment is stopped, tumours appear spontaneously or can be encouraged to re-appear with oestrogen therapy. These data clearly support the view that adjuvant clinical trials with tamoxifen should employ an indefinite treatment policy or at least until the time of treatment failure. Several clinical trials organisations in Great Britain (CRC and Scottish trial) have recruited a significant number of premenopausal patients. However, unlike postmenopausal patients, long-term tamoxifen therapy of premenopausal women often causes an increase in circulating oestrogen. Since tamoxifen has been shown to be a competitive inhibitor of oestrogen action, strategies to reduce ovarian steroidogenesis (oophorectomy or Zodalex®) may provide an optimal environment to sustain the long-term effectiveness of adjuvant tamoxifen therapy. Copyright © Royal Society of Edinburgh 1989 Oestrogen Deprivation - Antioestrogens nationallicence Proceedings of the Royal Society of Edinburgh. Section B. Biological Sciences Royal Society of Edinburgh Scotland Foundation 95(1989), 239-246 0269-7270 95<239 1989 95 PRB https://doi.org/10.1017/S026972700001071X text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1017/S026972700001071X text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Jordan V. Craig Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison, WI 53792, U.S.A NATIONALLICENCE 773 0- Proceedings of the Royal Society of Edinburgh. Section B. Biological Sciences Royal Society of Edinburgh Scotland Foundation 95(1989), 239-246 0269-7270 95<239 1989 95 PRB CC0 http://creativecommons.org/publicdomain/zero/1.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-cambridge